HighGravityDataEdwards Lifesciences — Feb 10, 2026 release
Fiscal 2025 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001099800-26-000006
Showing in the filing
EPS
“$2.90 to $3.05”
Period
FY2026
Measure
GAAP-tied
Source
Prose
All guidance in this release · 14
Constant currency sales growth for FY2026
“8 – 10%”
TMTT revenue growth for FY2026
“35 – 45% to $740 – $780 million”
TMTT growing for FY2026
“35 – 45%”
TMTT growth for FY2026
“35 – 45%”
TMTT revenue for FY2026
“$740 – $780 million”
TMTT sales for FY2026
“$740 – $780 million”
Adjusted EPS for FY2026
“$2.90 – $3.05”
Adjusted gross profit margin for FY2026
“between 78% and 79%”
R&D as a percentage of sales for FY2026
“approximately 17%”
Operating profit margin for FY2026
“at the high end of the original 28% to 29% guidance range”
Sales growth rate for FY2026
“8 to 10%”
EPS for FY2026
“$2.90 to $3.05”
Total sales for Q1 FY2026
“between $1.55 and $1.63 billion”
Adjusted EPS for Q1 FY2026
“$0.70 to $0.76”
Exhibit 99.1 · the passage around this item
… earlier in the release
Cash and cash equivalents were approximately $3.0 billion as of Dec. 31, 2025. Total debt was approximately $600 million. Outlook Edwards has increased confidence in meeting its 2026 sales growth rate guidance of 8 to 10% and EPS guidance of $2.90 to $3.05. For the first quarter of 2026, the company projects total sales to be between $1.55 and $1.63 billion and adjusted EPS of $0.70 to $0.76. 3 About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube. Conference Call and Webcast Information The company will be hosting a conference call today at 2:00 p.m. PT to discuss its fourth quarter results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com or www.edwards.com. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.